A Phase II randomized multicenter study to assess the efficacy of lenalidomide with or without erythropoietin and granulocyte-colony stimulating factor in patients with low and intermediate-1 risk myelodysplastic syndrome.

Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON) P/a HOVON Data CenterErasmus MC - Postbus 2040; 3000 CA Rotterdam; Tel: +31 10 704 1560 Fax: +31 10 704 1028; e-mail: hdc@erasmusmc.nl0 个研究点目标入组 200 人开始时间: 待定最近更新: 2024年2月28日

研究概览

简要总结

/A

研究设计

研究类型: Interventional

入排标准

入选标准

•1. Patients with MDS classified as:
•RA, RARS and RAEB (with <10% myeloid blasts), CMML (with <10% myeloid blasts), according to FAB, or;

排除标准

•1. Severe cardiac, pulmonary, neurologic, metabolic or psychiatric diseases or active malignancies;
•2. Anemia due to other causes than MDS including iron, B12 and folate deficiencies, auto-immune hemolysis and/or paroxysmal noctural hemoglobinuria (PNH);

研究者

发起方

Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON) P/a HOVON Data CenterErasmus MC - Postbus 2040; 3000 CA Rotterdam; Tel: +31 10 704 1560 Fax: +31 10 704 1028; e-mail: hdc@erasmusmc.nl

相似试验

招募中

不适用

A randomized phase II multicenter study to assess the tolerability and efficacy of the addition of ibrutinib to 10-day decitabine in UNFIT (i.e. HCT-CI >= 3) AML and high risk myelodysplasia (MDS) (IPSS-R > 4.5) patients aged >= 66 years.A study in the frame of the masterprotocol of parallel randomized phase II studies in UNFIT-older AML/high-risk MDS patients.Acute Myeloid Leukemia (AML), Myelodysplasia

NL-OMON19923HOVON Data Center185

已完成

2 期

Lapatinib in Combination With VinorelbineCancer

NCT01013740Novartis Pharmaceuticals112

招募中

1 期

GNT0006 gene therapy trial in patients with limb-girdle muscular dystrophyFKRP-related limb-girdle muscular dystrophy (LGMD R9)MedDRA version: 20.0Level: PTClassification code: 10028356Term: Muscular dystrophy Class: 100000004850

CTIS2023-506677-36-00Atamyo Therapeutics40

进行中（未招募）

1 期

GNT0006 gene therapy trial in patients with limb-girdle muscular dystrophyFKRP-related limb-girdle muscular dystrophy (LGMD R9)MedDRA version: 20.0Level: PTClassification code 10028356Term: Muscular dystrophySystem Organ Class: 10010331 - Congenital, familial and genetic disorders

EUCTR2021-004276-33-DKAtamyo Therapeutics39

招募中

不适用

A randomized phase II multicenter study with a safety run-in to assess the tolerability and efficacy of the addition of oral lenalidomide to standard induction therapy in AML and RAEB ≥ 66 years and very poor risk AML ≥ 18 years.

NL-OMON25046HOVON foundation200